SCHEMBL2464653

SCHEMBL2464653

CCCCCCC(=O)OS(=O)(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.55
LMNA P02545 2/20 0.52
PAM P19021 2/20 0.50
MAPT P10636 2/20 0.48
MAPK1 P28482 1/20 0.48
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TSHR P16473 4/20 0.47
PPARG P37231 5/20 0.46
PPARD Q03181 5/20 0.46
PPARA Q07869 5/20 0.46
HDAC11 Q96DB2 4/20 0.46
GPR84 Q9NQS5 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689556 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL3762292 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL339526 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL6688849 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL3846923 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1827580 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL5431993 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1445754 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1593662 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
Octane SCHEMBL27910076 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119278054-A Glycosylated prodrugs 莱顿大学 2025-01-07 CN disclosed
CN-119012999-A Improved nasal administration of pharmaceutical formulations 思瑞诺医疗有限公司 2024-11-22 CN disclosed
WO-2023183285-A1 METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION (US) 2023-09-28 WO disclosed
CN-115844903-A Application of betulin derivative in preparation of bacteria inhibiting medicine 潍坊赛宝工业技术研究院有限公司 2023-03-28 CN disclosed
CN-114206396-A Methods and compositions for attenuating an immune response against an antiviral transfer vector 西莱克塔生物科技公司 2022-03-18 CN disclosed
EP-3755697-A1 DEGRADERS OF EGFR AND METHODS OF USE THEREOF Dana Farber Cancer Institute, Inc. (US) 2020-12-30 EP disclosed
WO-2019164953-A1 DEGRADERS OF EGFR AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-29 WO disclosed
US-20110218343-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GLIAMED, INC. (US) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218343-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY FKBP8, FKBP1A, FKBP2 DGKA 4183/4885LMNA 4868/4885PAM 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.